What is InspireMD?
Headquartered in Tel Aviv, Israel, InspireMD, Inc. operates at the intersection of advanced engineering and interventional cardiology. The company is primarily focused on the development and commercialization of its proprietary MicroNet stent platform, a technology designed to address the limitations of traditional stenting in vascular and coronary applications. By integrating a fine mesh sleeve over the stent, the MicroNet technology provides enhanced embolic protection, a critical factor in reducing the risk of stroke during carotid artery procedures. Listed on the NYSE American under the ticker symbol NSPR, the company maintains a clear market position as an innovator in the medical device sector, specifically targeting high-growth segments within cardiovascular health. Its commitment to clinical excellence and long-term patient outcomes has made it a focal point for institutional investors seeking exposure to disruptive life sciences technologies.
How much funding has InspireMD raised?
InspireMD has raised a total of $109.1M across 3 funding rounds:
Debt
$11M
Private Equity
$40.1M
Stock/Share Issuance
$58M
Debt (2012): $11M, investors not publicly disclosed
Private Equity (2025): $40.1M, investors not publicly disclosed
Stock/Share Issuance (2025): $58M supported by OrbiMed
Key Investors in InspireMD
OrbiMed
OrbiMed Advisors LLC is a premier investment firm dedicated exclusively to the healthcare sector, providing capital and strategic guidance to companies across the biopharmaceutical, medical device, and digital health landscapes. The firm leverages deep life sciences expertise to support innovation from early-stage development through to commercial maturity.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for InspireMD?
With the successful closure of this major strategic investment, InspireMD is poised to enter a new phase of operational expansion. The company is expected to prioritize the scaling of its manufacturing capabilities and the broadening of its commercial footprint in key international markets. Strategic focus will likely remain on securing regulatory milestones and expanding the clinical evidence base for the MicroNet platform, which is essential for driving physician adoption and market penetration. Furthermore, the company will likely utilize this capital to optimize its supply chain and enhance its research and development pipeline, ensuring that its product offerings remain at the forefront of vascular intervention. As the firm continues to execute its growth strategy, the integration of this new financing will be instrumental in sustaining its competitive advantage and achieving long-term value creation for its shareholders.
See full InspireMD company page
